Worldwide Healthcare Trust PLC Edison issues review on Worldwide Healthcare Trust
March 26 2018 - 8:11AM
RNS Non-Regulatory
TIDMWWH
Worldwide Healthcare Trust PLC
26 March 2018
London, UK, 26 March 2018
Edison issues review on Worldwide Healthcare Trust (WWH)
Worldwide Healthcare Trust (WWH) is managed by OrbiMed Capital,
a leading specialist healthcare investment company. Since December
2017, following the departure of Sam Isaly, its lead manager is
Sven Borho, who is a founding partner of OrbiMed and has been
involved with the management of WWH since the trust's launch in
April 1995. Borho is bullish on the outlook for the global
healthcare sector due to continued innovation, a benign regulatory
environment, an expected acceleration in mergers and acquisitions,
and inexpensive company valuations. WWH has a positive long-term
performance track record. Its NAV and share price total returns
have exceeded the MSCI World Health Care index total returns over
one, three, five and 10 years.
WWH's share price discount to cum-income NAV has narrowed
meaningfully from 13.0% at end-June 2016 following the UK's
European referendum, and in recent months the trust has been
trading close to NAV. Over the last 12 months, WWH has traded at an
average premium of 0.3%, which compares to the average discounts
over the last three, five and 10 years of 3.3%, 3.4% and 5.7%
respectively. While WWH aims to generate long-term capital growth,
rather than income, the trust pays dividends regularly twice a
year; its current yield is 0.9%.
Click here to view the full report.
All reports published by Edison are available to download free
of charge from its website
www.edisoninvestmentresearch.com
About Edison: Edison is an investment research and advisory
company, with offices in North America, Europe, the Middle East and
AsiaPac. The heart of Edison is our world-renowned equity research
platform and deep multi-sector expertise. At Edison Investment
Research, our research is widely read by international investors,
advisers and stakeholders. Edison Advisors leverages our core
research platform to provide differentiated services including
investor relations and strategic consulting.
Edison is authorised and regulated by the Financial Conduct
Authority.
Edison is not an adviser or broker-dealer and does not provide
investment advice. Edison's reports are not solicitations to buy or
sell any securities.
For more information please contact Edison:
Mel Jenner, +44 (0)20 3077 5720
Sarah Godfrey, +44 (0)20 3681 2519
investmenttrusts@edisongroup.com
Learn more at www.edisongroup.com and connect with Edison
on:
LinkedIn https://www.linkedin.com/company/edison-investment-research
Twitter www.twitter.com/Edison_Inv_Res
YouTube www.youtube.com/edisonitv
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAJFMTTMBMTBAP
(END) Dow Jones Newswires
March 26, 2018 08:11 ET (12:11 GMT)
Finsbury Worldwide Pharm (LSE:FWP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Finsbury Worldwide Pharm (LSE:FWP)
Historical Stock Chart
From Jul 2023 to Jul 2024